ABSTRACT
The speculation that impairments in dopamine circuitry lie at the heart of the susceptibility to schizophrenia has long been debated but, recently, new evidence has arisen to support it. Dopamine mimetics such as L-dopa, amphetamine, and disulfiram are well known to produce psychotic symptoms de novo or to worsen pre-existing ones. Recent evidence shows that amphetamine causes a twofold higher release of dopamine in individuals with schizophrenia than it does in control subjects [1,2].
